About Cellective BioTherapy
Cellective BioTherapy is a company based in Durham (United States) founded in 2015. Cellective BioTherapy has raised $2.5 million across 1 funding round from investors including Eshelman Ventures. Cellective BioTherapy operates in a competitive market with competitors including Be Bio, Immusoft, JW Therapeutics, Walking Fish Therapeutics and Overland Pharmaceuticals, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
May 26, 2015
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cellective BioTherapy
Cellective BioTherapy has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellective BioTherapy
Cellective BioTherapy has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Eshelman Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Cellective BioTherapy
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellective BioTherapy
Investment portfolio details for Cellective BioTherapy
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellective BioTherapy
Detailed financials for Cellective BioTherapy
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellective Biotherapy Comparisons
Peer comparison for Cellective BioTherapy
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellective BioTherapy
Cellective BioTherapy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Be Bio, Immusoft, JW Therapeutics, Walking Fish Therapeutics and Overland Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
B cell therapies are developed for oncology and rare diseases.
|
|
| Locked | Locked | Locked |
B cells are programmed as biofactories for therapeutic protein delivery.
|
|
| Locked | Locked | Locked |
Cell immunotherapy products are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Cell-based therapeutics for cancer and immunological disorders are developed.
|
|
| Locked | Locked | Locked |
-
|
Detailed competitors of Cellective BioTherapy
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellective Biotherapy
Complete news archive for Cellective BioTherapy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellective BioTherapy
Cellective BioTherapy was founded in 2015.
Cellective BioTherapy is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Cellective BioTherapy is a funded company, having raised a total of $2.5M across 1 funding round to date.
Cellective BioTherapy was founded in 2015 and is based in Durham, United States. Operations center on the biotechnology sector, where B cell-based cellular therapies are developed to address cancers, autoimmunity, and immunodeficiency. Human B cells are expanded ex vivo through proprietary technology for autologous immunotherapy applications, including treatments for immunodeficiency. The companys domain is cellectivebiotherapy.com.
Cellective BioTherapy's top competitors include Be Bio, Immusoft and JW Therapeutics.
Cellective BioTherapy has 1 investor. Key investors include Eshelman Ventures.